p-Cbl (Y674) pAb detects endogenous levels of Cbl only when phosphorylated at Tyr674.
Applications:
WB, IHC
Reactivity:
Human, Mouse, Rat
Immunogen:
Synthetic phosphopeptide derived from human Cbl around the phosphorylation site of Tyrosine 674.
Host:
Rabbit
Clonality:
Polyclonal
Conjugate:
Unconjugated
Molecular Weight:
~ 100, 120kDa
Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Product Form:
1mg/ml in PBS?with?0.1%?Sodium?Azide,?50%?Glycerol.
Target
Function:
Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3.
Involvement in Disease:
Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia: A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia.
Post-Translational Modification:
Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues in response to FLT1 and KIT signaling. Phosphorylated on tyrosine residues by INSR and FGR. Phosphorylated on several tyrosine residues by constitutively activated FGFR3. Not phosphorylated at Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by HCK.
Cellular Location:
Cytoplasm. Cell membrane.
Colocalizes with FGFR2 in lipid rafts at the cell membrane.
Database Links:
Entrez Gene: 867?Human
Entrez Gene: 12402?Mouse
Entrez Gene: 500985?Rat
Omim: 165360?Human
SwissProt: P22681?Human
SwissProt: P22682?Mouse
Unigene: 504096?Human
Unigene: 266871?Mouse
Synonyms:
4732447J05Rik Antibody
C CBL Antibody
Cas Br M (murine) ecotropic retroviral transforming sequence Antibody
Casitas B lineage lymphoma proto oncogene Antibody